BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 17, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SAR 1118: Phase II data

In a double-blind Phase II trial in 230 patients, 0.1%, 1% and 5% formulations of twice-daily topical SAR 1118 improved corneal staining and patient symptoms at week 12 vs. placebo. SAR 1118...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >